Related Experiment Video
Updated: May 13, 2025

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Ganoderic Acid A Prevented Osteoporosis by Modulating the PIK3CA/p-Akt/TWIST1 Signaling Pathway
Jianyu Zhao1, Ying Fan2, Hao Li2
1Department of Orthopaedics, the First Affiliated Hospital Dalian Medical University Dalian China.
Abstract:
Osteoporosis is a disorder of decreased bone mass, microarchitectural deterioration, and fragility fractures. Ganoderma lucidum has been reported to have a variety of pharmacological activities, including immune regulation, anti-inflammation, antioxidation, sedative hypnosis, blood sugar and lipid regulation, and so on. However, the effective ingredients and the underlying mechanism of Ganoderma lucidum against osteoporosis are rarely clarified. Ganoderic acid A (GA-A), a triterpenoid, is one of the main components of Ganoderma lucidum. Our previous preliminary bioinformatic study found that it may affect bone metabolism, and it has been reported that GA-A has anti-osteoporosis potential via regulating MC3T3-E1 cells' osteogenic differentiation activity. Therefore, the aim of this study is to investigate the effects of Ganoderic acid A in preventing osteoporosis and uncover the potential mechanisms. In vivo, the 8-week-old C57BL/6J female mice were used to establish the osteoporosis model by ovariectomy (OVX). Two cell lines, MC3T3-E1 cells and primary osteoblasts, were used and induced with hydrogen peroxide (H2O2) to the state of oxidative stress in osteoporosis in vitro. We showed that Ganoderic acid A could inhibit OVX-induced bone loss in a dose-dependent manner and promote H2O2-induced osteogenic differentiation of primary osteoblasts and MC3T3-E1 cells. The mechanism-related signaling pathways were identified by network pharmacology screening and verified by bioinformatics. Results predicted that the target of Ganoderic acid A might be PIK3CA. Mechanistically, we found that PIK3CA activated the Akt receptor, then inhibited the expression of TWIST1 in the osteoblasts to up-regulate the protein expression of the osteogenic-related markers. Our results suggested that Ganoderic acid A could prevent OVX-induced osteoporosis and promote H2O2-induced osteogenic differentiation of primary osteoblasts and MC3T3-E1 cells. Ganoderic acid A might play an important role in the prevention of osteoporosis by modulating the PIK3CA/p-Akt/TWIST1 signaling pathway.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Osteoclasts in Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
TGF - β Signaling Pathway
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Inhibition of Cdk Activity

